House dust mite allergy immunotherapy - ASIT biotech

Drug Profile

House dust mite allergy immunotherapy - ASIT biotech

Alternative Names: hdm-ASIT+

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ASIT biotech
  • Class Allergy immunotherapies; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Rhinoconjunctivitis

Most Recent Events

  • 17 Oct 2017 ASIT biotech has patent protection for House dust mite allergy immunotherapy in Europe, China, Japan and India
  • 29 Mar 2017 ASIT biotech completes a phase II trial in Rhinoconjunctivitis in Germany (SC) (EudraCT2016-000557-13) before March 2017
  • 30 Nov 2016 ASIT biotech completes enrolment in its phase IIa trial for Rhinoconjunctivitis in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top